The authors declare that they have no competing interests.
GM performed the analysis of data, and drafted the manuscript. SL provided language help and writing assistance. MLZ carried out a literature review about the topic. CF participated in data collecting. AS collected and reported adverse drug reactions data. AM conceived of the study, and participated in its design. FM participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
Short-term administration of diosmin is usually considered safe, with only minor side effects (stomach and abdominal pain, diarrhea, dermatological disorders, and headache) occasionally observed. Within a 4-year period, a general practitioner noticed 17 cases of mild, diosmin-induced side effects, two of which showed particular interest.
Case 1: A 55-year-old Caucasian woman presented with chronic leg venous insufficiency. She was prescribed diosmin 450mg twice a day. After 5 days of therapy, she developed pain in the legs (myalgia), and diosmin therapy was suspended. She made a spontaneous attempt of drug rechallenge and her leg pain reappeared. Thus, she underwent blood analysis, which showed elevation of creatine phosphokinase levels. Creatine phosphokinase values normalized only after prolonged discontinuation of the therapy. Case 2: A 79-year-old Caucasian man, who was diagnosed with acute hemorrhoidal syndrome. After 21 days of continuous diosmin treatment, increased levels of serum lactic dehydrogenase were detected. In both cases a comprehensive analysis of all possible causes for enzyme elevation was made.
A feasible hypothesis to explain these rare effects could be that exaggerated adrenergic activity occurred on microcirculation, leading to an excessive peripheral vasoconstriction and subsequent ischemic damage. An individual predisposition is strongly suggested. A concurrence of events was probably responsible for the elevation of nonspecific tissue necrosis markers. Physicians and patients must be aware of these rare, but possible, adverse drug reactions.
Diosmin monograph. Altern Med Rev. 2004, 9: 308-311.
Boudet C, Peyrin L: Comparative effect of tropolone and diosmin on venous COMT and sympathetic activity in rat. Arch Int Pharmacodyn Ther. 1986, 283: 312-320. PubMed
Labrid C: A lymphatic function of Daflon 500mg. Int Angiol. 1995, 14: 36-38. PubMed
Cova D, De Angelis L, Giavarini F, Palladini G, Perego R: Pharmacokinetics and metabolism of oral diosmin in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1992, 30: 29-33. PubMed
Drugcite: Adverse event categories for diosmin. [ http://www.drugcite.com/?q=diosmin]
Meyer OC: Safety and security of Daflon 500mg in venous insufficiency and in hemorrhoidal disease. Angiology. 1994, 45: 579-584. PubMed
Middleton E, Kandaswami C, Theoharides TC: The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev. 2000, 52: 673-751. PubMed
- Uncommon serum creatine phosphokinase and lactic dehydrogenase increase during diosmin therapy: two case reports
Maria Laura Zuccoli
- BioMed Central